BAX Stock Analysis — Baxter International
Sector: Healthcare
AI Verdict
Baxter is cheap for the sector at 10.4x forward earnings, but the discount reflects real concerns about shrinking sales and the risk of further downside if the core hospital business doesn't stabilize.
Competitive Moat
Baxter International manufactures essential hospital products like IV solutions, infusion pumps, and renal care devices, making it deeply embedded in hospital supply chains. Its moat comes from high switching costs and regulatory barriers in medical device approval, which protect its established product lines.
Summary
Baxter trades at just 10.4x next year's earnings, well below the healthcare sector median of 22x, after a year of underperformance.
Where It Stands
The stock is down -26.96% over the past year, with a forward P/E of 10.4x and an RSI of 65.4 signaling elevated pullback risk.
Key Metrics
- RSI: 65.4 — Near Overbought
- Forward P/E: 10.4x
- Revenue Growth: -0.0%
- Market Cap: $11.7B
- Dividend Yield: 0.00%
- 1-Year Return: -26.96%
- 52-Week High: $31.76
- 52-Week Low: $15.73
Analyst Consensus
1 Buy · 16 Hold · 7 Sell (24 analysts)
Bull Case
At 10.4x forward earnings, you're paying less than half the sector average for a business with entrenched hospital relationships.
Bear Case
With an RSI of 65.4 and trailing revenue down -4.8% year-over-year, any P/E rerating could easily wipe out recent gains.
Catalyst to Watch
Watch for next quarter's earnings and any signs of revenue stabilization or recovery, as continued declines could justify the low multiple.